TNF and AA amyloidosis: The availability of new treatments over the last decade, including biologic disease modifying antirheumatic drugs (b-DMARD) such as inhibitors of TNF-α (anti-TNFs), have revolutionized the treatment, demonstrating improved efficacy in controlling the disease activity of patients with inflammatory rheumatic diseases and resistant or intolerant to conventional synthetic DMARDs.5 Controlling the underlying disease activity and suppression of the acute phase response are essential in the treatment of AA amyloidosis accompanying a chronic inflammatory disease.